Gynoxin (Fenticonazole Nitrate)

Gynoxin is indicated for the topical treatment of fungal infections of the female genital tract.

• Vulvovaginal candidiasis caused by Candida species.
• Acute yeast infection of the vagina with symptoms such as itching, burning, and discharge.
• Maintenance therapy to prevent recurrence after successful initial treatment.
• Treatment of mixed infections when Candida coexists with bacterial vaginosis, as directed by a clinician.
• Use in patients with recurrent vulvovaginal yeast infections who have responded to prior courses of antifungal therapy.
• Application in cases where topical azole therapy is preferred over oral agents due to drug interactions or systemic contraindications.

The safety profile of Gynoxin reflects the typical adverse events associated with intravaginal imidazole antifungals.

Common

• Mild vaginal irritation or burning sensation.
• Local itching or redness at the application site.
• Unpleasant vaginal discharge with a slight odor.
• Headache or mild dizziness (occasionally reported).
• Slight abdominal discomfort or cramping.

Serious

• Severe allergic reaction such as rash, hives, or swelling of the face and throat.
• Persistent or worsening vaginal irritation that does not improve after several days.
• Signs of secondary bacterial infection, including fever or foul‑smelling discharge.
• Rare cases of liver enzyme elevation (monitor if clinically indicated).

Before prescribing Gynoxin, clinicians should evaluate patient history and consider specific safety considerations.

• Confirm diagnosis of a fungal infection before initiating therapy.
• Avoid use if the patient has a known hypersensitivity to fenticonazole or other imidazole antifungals.
• Do not use in the presence of active vaginal bleeding or severe mucosal trauma.
• Use caution in pregnancy or lactation; evaluate risks and benefits.
• Advise patients to complete the full course even if symptoms improve.
• Watch for secondary infection if symptoms continue after treatment.

Gynoxin may interact with other medications or products applied to the vagina; awareness of potential interactions helps ensure safe use.

Avoid

• Concurrent use of intravaginal products containing spermicides, douches, or other antifungal agents, as they may reduce efficacy.
• Systemic azole antifungals (e.g., fluconazole) taken orally, which could increase the risk of additive toxicity.

Use with caution

• Hormonal contraceptives administered vaginally, such as rings, may be displaced; advise proper timing of application.
• Topical corticosteroids applied to the vagina may mask irritation; monitor patient response.
• Patients on hepatotoxic drugs should be observed, although systemic absorption of Gynoxin is minimal.